CGT021 oligonucleotide against E2F cell cycle transcription factor regulatory update

The FDA granted Orphan Drug designation for CGT021 to prevent arterio-venous graft failure in end-stage renal disease patients who require hemodialysis. Corgentech expects to begin shortly a Phase I/I...